8-89980789-T-C
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS1
The NM_002485.5(NBN):āc.425A>Gā(p.Asn142Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000211 in 1,613,620 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N142D) has been classified as Uncertain significance.
Frequency
Consequence
NM_002485.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NBN | NM_002485.5 | c.425A>G | p.Asn142Ser | missense_variant | 4/16 | ENST00000265433.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NBN | ENST00000265433.8 | c.425A>G | p.Asn142Ser | missense_variant | 4/16 | 1 | NM_002485.5 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000335 AC: 51AN: 152186Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000167 AC: 42AN: 251294Hom.: 0 AF XY: 0.000184 AC XY: 25AN XY: 135820
GnomAD4 exome AF: 0.000198 AC: 290AN: 1461318Hom.: 0 Cov.: 31 AF XY: 0.000213 AC XY: 155AN XY: 727018
GnomAD4 genome AF: 0.000335 AC: 51AN: 152302Hom.: 0 Cov.: 32 AF XY: 0.000363 AC XY: 27AN XY: 74478
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | May 15, 2023 | In the published literature, this variant has been reported in individuals with breast and/or ovarian cancer (PMIDs: 34646395 (2021) and 26315354 (2015)), chronic myelomonocytic leukemia (PMID: 26979391 (2016)), as well as unaffected individuals (PMID: 24728327 (2014), 24894818 (2014), 26315354 (2015), 31206626 (2019)). The frequency of this variant in the general population, 0.00042 (15/35422 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Aug 23, 2020 | This variant is associated with the following publications: (PMID: 23525077, 26315354, 24728327, 26787654, 24894818, 26979391, 26193622, 12376507, 12427538, 31278556) - |
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 02, 2017 | - - |
Microcephaly, normal intelligence and immunodeficiency Uncertain:1Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | May 18, 2021 | - - |
not specified Uncertain:1Benign:1Other:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 25, 2024 | Variant summary: NBN c.425A>G (p.Asn142Ser) results in a conservative amino acid change located in the BRCT domain of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00018 in 258668 control chromosomes, predominantly at a frequency of 0.00043 within the Latino subpopulation in the gnomAD database. The observed variant frequency within Latino control individuals in the gnomAD database is approximately 3.44 fold of the estimated maximal expected allele frequency for a pathogenic variant in NBN causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (0.00013). This variant has also been reported in the FLOSSIES database among women older than age 70 who have never had cancer. c.425A>G has been reported in the literature as a non-deleterious variant or a VUS in settings of multigene panel testing among individuals affected with breast and/or ovarian cancer (example, Ramus_2015, Young_2016, Weitzel_2019, Laraqui_2021, deOlivier_2022) and in at least one patient with hypogammaglobulinemia and lymphoma (example: Allain_2023). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 36155879, 24728327, 23525077, 34646395, 12376507, 31278556, 26315354, 12427538, 31206626, 26787654, 35534704). ClinVar contains an entry for this variant (Variation ID: 127871). Based on the evidence outlined above, the variant was classified as likely benign. - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jun 17, 2015 | - - |
Hereditary cancer-predisposing syndrome Benign:2
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Jun 21, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 19, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Aplastic anemia;C0023449:Acute lymphoid leukemia;C0398791:Microcephaly, normal intelligence and immunodeficiency Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 23, 2017 | - - |
Malignant tumor of breast Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The NBN p.Asn142Ser variant was identified in 4 of 9094 proband chromosomes (frequency: 0.0004) from individuals or families with myeloproliferative neoplasms, epithelial ovarian cancer, or breast cancer and in 4 of 8224 control chromosomes (frequency: 0.0005) from healthy individuals (Bodian 2014, Pratz 2016, Ramus 2015, Young 2016). The variant was also identified in dbSNP (ID: rs769414) as "With other allele", ClinVar (classified as likely benign by Invitae and GeneDx; and as uncertain significance by Ambry Genetics and four other clinical laboratories), Cosmic (1x in oesophagus), LOVD 3.0 (1x), and Zhejiang University database. The variant was identified in control databases in 47 of 277032 chromosomes at a frequency of 0.0002 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European in 24 of 126600 chromosomes (freq: 0.0002), African in 1 of 24028 chromosomes (freq: 0.00004), Other in 7 of 6460 chromosomes (freq: 0.001), Latino in 12 of 34412 chromosomes (freq: 0.0004), Ashkenazi Jewish in 2 of 10148 chromosomes (freq: 0.0002), and South Asian in 1 of 30782 chromosomes (freq: 0.00003); it was not observed in the East Asian or Finnish populations. The p.Asn142 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and 2 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Hereditary cancer Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | Jan 23, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at